Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A2PA
|
|||
| Former ID |
DNCL002485
|
|||
| Drug Name |
IMF-001
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
ImmunoFrontier Tokyo, Japan
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01234012) Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.